Bausch Health Files 8-K on Definitive Agreement

TL;DR

Bausch Health just signed a big deal, check the 8-K.

AI Summary

Bausch Health Companies Inc. filed an 8-K on December 29, 2025, reporting on events that occurred on December 26, 2025. The filing indicates the entry into a material definitive agreement and the creation of a direct financial obligation. The company, formerly known as Valeant Pharmaceuticals International, Inc., is based in Laval, Quebec.

Why It Matters

This 8-K filing signals a significant new agreement or financial commitment for Bausch Health, which could impact its financial obligations and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements and new financial obligations can introduce new risks or alter existing ones for a company.

Key Players & Entities

• Bausch Health Companies Inc. (company) — Registrant
• Valeant Pharmaceuticals International, Inc. (company) — Former Company Name
• December 26, 2025 (date) — Date of earliest event reported
• December 29, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $1.6 billion — Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00
• $4.4 billion — form a single series with the Issuer's $4.4 billion principal amount of 10.00% Senior Secur

Filing Documents

• bhc-20251226.htm (8-K) — 38KB
• exhibit42-126numbercox2025.htm (EX-4.2) — 95KB
• 0000885590-25-000059.txt ( ) — 259KB
• bhc-20251226.xsd (EX-101.SCH) — 2KB
• bhc-20251226_lab.xml (EX-101.LAB) — 22KB
• bhc-20251226_pre.xml (EX-101.PRE) — 13KB
• bhc-20251226_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement Exchange Offers On December 26, 2025 (the "Settlement Date"), Bausch Health Companies Inc. (the "Company") and its indirect wholly owned subsidiary 1261229 B.C. Ltd. (the "Issuer") completed the previously announced offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028 for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 (the "New Notes" and, such offers, the "Offers"), in each case, pursuant to the terms described in a confidential exchange offer memorandum dated November 24, 2025 (the "Exchange Offer Memorandum"). Pursuant to the Offers, the Issuer issued an aggregate principal amount of $1.6 billion of New Notes. The New Notes have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. Indenture The New Notes were issued on the Settlement Date pursuant to the indenture, dated as of April 8, 2025 (the "Original Indenture"), by and among the Issuer, the Company and other guarantors named therein, The Bank of New York Mellon as trustee, registrar and paying agent, and the notes collateral agents named therein, as supplemented by the second supplemental indenture, dated as of December 26, 2025 (the "Second Supplemental Indenture", and together with the Original Indenture, the "Indenture"), by and among the Issuer, the Company and other guarantors named therein, The Bank of New York Mellon, as trustee, registrar, and paying agent, and the notes collateral agents named therein. Pursuant to the Second Supplemental Indenture, the New Notes form a single series with the Issuer's $4.4 billion principal amount of 10.00% Senior Secured Notes due 2032 (the "Existing Numberco Notes") that were issued o

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Number Description 4.1 Indenture, dated as of April 8, 2025, by and among 1261229 B.C. Ltd., Bausch Health Companies Inc., the other guarantors party thereto, The Bank of New York Mellon, as trustee and the notes collateral agents party thereto (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on April 9, 2025) 4.2* Second Supplemental Indenture, dated as of December 29, 2025, by and among 1261229 B.C. Ltd., Bausch Health Companies Inc., the other guarantors party thereto, The Bank of New York Mellon, as trustee and the notes collateral agents party thereto 4.3 Form of Note (Included in Exhibit 4.1) 101.SCH* XBRL Taxonomy Extension Schema Document 101.LAB* XBRL Taxonomy Extension Label Linkbase Document 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document 104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) ____________________________________ * Filed herewith.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 29, 2025 BAUSCH HEALTH COMPANIES INC. By: /s/ Jean-Jacques Charhon Jean-Jacques Charhon Executive Vice President, Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR